Ribosomal Protein S6 Phosphorylation is Associated with Epithelial Dysplasia and Squamous Cell Carcinoma of the Oral Cavity
Tóm tắt
Ribosomal protein S6 (RPS6), a downstream effector of the mammalian target of rapamycin pathway (mTOR), is activated in many cancers including oral squamous cell carcinoma (OSCC). However, the role of RPS6 in the progression of potentially malignant disorders (or premalignant lesions) to OSCC is unknown. The purpose of this study was to examine the expression of RPS6 in epithelial dysplasia and OSCC to determine the association of RPS6 in tumor progression. In our study, an immunohistochemical analysis of RPS6 was performed on tissue microarrays containing 30 control samples, 15 epithelial dysplasia cases, and 53 OSCC cases. Correlations between the clinicopathologic features of OSCC and RPS6 expression were analyzed using the Chi-square test. We found RPS6 phosphorylation (p-RPS6) in 15/30 (50 %) control normal oral mucosa samples, 15/15 (100 %) epithelial dysplasia cases, and 47/53 (88.68 %) OSCC cases. The frequency of p-RPS6 in epithelial dysplasia or OSCC showed a statistically significant difference compared to control (P < 0.001). However, there were no significant correlations between p-RPS6 and the clinicopathologic features of OSCC. Our findings suggest that RPS6 activation is associated with the early events of tumor progression, suggesting p-RPS6 as a potential marker for early detection of oral cancer.
Tài liệu tham khảo
Johnson NW, Jayasekara P, Amarasinghe AA (2011) Squamous cell carcinoma and precursor lesions of the oral cavity: epidemiology and aetiology. Periodontol 2000 57(1):19–37
Warnakulasuriya S (2009) Global epidemiology of oral and oropharyngeal cancer. Oral Oncol 45:309–316
Napier SS, Speight PM (2008) Natural history of potentially malignant oral lesions and conditions: an overview of the literature. J Oral Pathol Med 37:1–10
Mithani SK, Mydlarz WK, Grumbine FL et al (2007) Molecular genetics of premalignant oral lesions. Oral Dis 13:126–133
Ruvinsky I, Meyuhas O (2006) Ribosomal protein S6 phosphorylation: from protein synthesis to cell size. Trends Biochem Sci 31:342–348
Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2:489–501
Ruvinsky I, Katz M, Dreazen A et al (2009) Mice deficient in ribosomal protein S6 phosphorylation suffer from muscle weakness that reflects a growth defect and energy deficit. PLoS One 4:e5618
Ruvinsky I, Sharon N, Lerer T, Cohen H, Stolovich-Rain M, Nir T, Dor Y, Zisman P, Meyuhas O (2005) Ribosomal protein S6 phosphorylation is a determinant of cell size and glucose homeostasis. Genes Dev 19(18):2199–2211
Clark C, Shah S, Herman-Ferdinandez L et al (2010) Teasing out the best molecular marker in the AKT/mTOR pathway in head and neck squamous cell cancer patients. Laryngoscope 120:1159–1165
Molinolo AA, Hewitt SM, Amornphimoltham P et al (2007) Dissecting the Akt/mammalian target of rapamycin signaling network: emerging results from the head and neck cancer tissue array initiative. Clin Cancer Res 13:4964–4973
Kononen J, Bubendorf L, Kallioniemi A et al (1998) Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4:844–847
Bose S, Chandran S, Mirocha JM et al (2006) The Akt pathway in human breast cancer: a tissue-array-based analysis. Mod Pathol 19:238–245
Pantuck AJ, Seligson DB, Klatte T et al (2007) Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer 109:2257–2267
Bjornsti MA, Houghton PJ (2004) The TOR pathway: a target for cancer therapy. Nat Rev Cancer 4:335–348
Scheper MA, Chaisuparat R, Nikitakis NG et al (2008) Expression and alterations of the PTEN/AKT/mTOR pathway in ameloblastomas. Oral Dis 14:561–568
Amornphimoltham P, Patel V, Sodhi A et al (2005) Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck. Cancer Res 65:9953–9961
Liu Y, Hidayat S, Su WH et al (2007) Expression and activity of mTOR and its substrates in different cell cycle phases and in oral squamous cell carcinomas of different malignant grade. Cell Biochem Funct 25:45–53
Garnis C, Buys TP, Lam WL (2004) Genetic alteration and gene expression modulation during cancer progression. Mol Cancer 3:9
Vitale-Cross L, Czerninski R, Amornphimoltham P et al (2009) Chemical carcinogenesis models for evaluating molecular-targeted prevention and treatment of oral cancer. Cancer Prev Res (Phila) 2:419–422
Feng CJ, Li HJ, Li JN et al (2008) Expression of Mcm7 and Cdc6 in oral squamous cell carcinoma and precancerous lesions. Anticancer Res 28:3763–3769
Inoue H, Miyazaki Y, Kikuchi K et al (2012) Podoplanin expression during dysplasia-carcinoma sequence in the oral cavity. Tumour Biol 33:183–194
Jham BC, Costa NL, Silva JM et al (2012) Midkine expression in oral squamous cell carcinoma and leukoplakia. J Oral Pathol Med 41:21–26
Kato Y, Uzawa K, Yamamoto N et al (2007) Overexpression of Septin1: possible contribution to the development of oral cancer. Int J Oncol 31:1021–1028
Montebugnoli L, Cervellati F, Cocchi R et al (2010) Immunohistochemical expression of p16(INK4A) protein as a helpful marker of a subset of potentially malignant oral epithelial lesions: study on a series with long-term follow-up. Histopathology 57:528–534
Nomura H, Uzawa K, Yamano Y et al (2009) Down-regulation of plasma membranous Annexin A1 protein expression in premalignant and malignant lesions of the oral cavity: correlation with epithelial differentiation. J Cancer Res Clin Oncol 135:943–949
Torres-Rendon A, Roy S, Craig GT et al (2009) Expression of Mcm2, geminin and Ki67 in normal oral mucosa, oral epithelial dysplasias and their corresponding squamous-cell carcinomas. Br J Cancer 100:1128–1134